

Subject: Sale of certain Excedrin® products halted

On October 7, 2020, GSK Consumer Healthcare, the makers of Excedrin®, requested that retailers stop selling specific lots of the product due to the possibility of holes in the product bottle caused by a manufacturing defect.¹

Specific Excedrin® products affected by the stop sale request include all 50, 80, 100, 125, 200, 250 and 300 count containers of:

- Excedrin® Migraine Caplets/Geltabs
- Excedrin® Extra Strength Caplets
- Excedrin® PM Headache Caplets
- Excedrin® Tension Headache Caplets

Products specifically not impacted by the stop sale request include:

- Excedrin® Extra Strength Caplets (24-count bottle)
- Excedrin® Migraine Caplets/Geltabs (24-count bottle)

The Impact

First Script® is reviewing the affected Excedrin® products dispensed through our systems. As these products are predominantly sold in over-the-counter retail settings, we do not expect a significant number of affected prescriptions.

Should specific questions or concerns arise, or for more information, please contact your Account Manager, Account Pharmacist or email us at: askthepharmacist@coventry.com.

1. Excedrin.com. Products. Excedrin Stop Sale Notification: October 7, 2020. Accessed at: <https://www.excedrin.com/products/discontinued/>